Zolpidem (Stilnox) And Insomnia Management - NPS Info For Prescribers And Patients, Australia

Main Category: Sleep / Sleep Disorders / Insomnia
Also Included In: Pharmacy / Pharmacist
Article Date: 11 Aug 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

To help prescribers and pharmacists counsel patients concerned about the sleep-related adverse effects associated with zolpidem (Stilnox), the National Prescribing Service Limited (NPS) has released a position statement on the drug and sleep-related behaviours.

NPS Deputy CEO, Karen Kaye said the position statement explains the background to the TGA's decision to impose a boxed warning on zolpidem and to describe the current place of this hypnotic drug in insomnia therapy.

The paper examines the evidence linking the medicine with bizarre sleep-related behaviours, such as sleepwalking, sleep-eating and sleep-driving. It also outlines treatments for insomnia and guidance for counselling patients, pointing GPs and pharmacists to the NPS Fact Sheet on zolpidem released in February this year.

Ms Kaye reminded prescribers that the many potential causes of insomnia should be addressed before making a treatment decision and that the risks associated with hypnotics generally outweigh any benefits they provide with continous long term use.

"NPS advises that patients should avoid alcohol, other CNS depressants, and higher than recommended doses of zolpidem - as these probably increase the risk of sleep-related events.

"However sleep-related events can occur with therapeutic doses of zolpidem in people without these or other predisposing factors. While these events are rare, they can have serious consequences, so consumers and their prescribers should weigh this up when deciding on how to manage sleep problems," Ms Kaye said.

Non-drug therapies are recommended as initial treatment for insomnia. These include sleep hygiene principles and stimulus control advice, sleep restriction, cognitive therapy, relaxation therapies, and regular exercise.

NPS advises prescribers to reserve short-acting benzodiazepines (eg, temazepam), zolpidem, or zopiclone for short-term severe insomnia, and for intermittent use in chronic severe insomnia that is unresponsive to non-drug therapies.

"For all hypnotics, use the lowest dose for the shortest time possible (ideally for less than two weeks) and re-evaluate within seven to fourteen days of starting therapy," Ms Kaye said.

The TGA recommends limiting use of zolpidem to a maximum of 4 weeks.

The position paper can be read online at the new-look NPS site http://www.nps.org.au. The NPS website design was updated this week to make searching for the most relevant and up-to-date information about medicines much easier.

National Prescribing Service Limited (NPS) is an independent, non-profit organisation for Quality Use of Medicines funded by the Australian Government Department of Health and Ageing.

National Prescribing Service Limited (NPS)